16 January 2024
\n \n \n \nThe Jenner Institute at NDM is conducting a new study using the Bacille Calmette-Gu\u00e9rin (BCG) vaccine, the only vaccine currently licensed against tuberculosis. People who have received the BCG vaccine previously will be given it again to compare whether giving it by inhalation is better at protecting people against tuberculosis than giving it through the skin.
\n \n\n \n \n11 January 2024
\n \n \n \nThe first clinical trial participants received doses of the ChAdOx1 NipahB vaccine this week at the University of Oxford. This is the first-in-human trial of the vaccine, being developed by researchers at the Pandemic Sciences Institute.
\n \n\n \n \n4 January 2024
\n \n \n \nThe R21/Matrix-M malaria vaccine developed by The Jenner Institute and the Serum Institute of India, is one step closer to mass rollout, after officially receiving WHO prequalification status, making it eligible for procurement by United Nations agencies.
\n \n\n \n \n3 January 2024
\n \n \n \nA partnership between CEPI, Barinthus Biotherapeutics and the University of Oxford aims to fast-track the development of a potential vaccine for the prevention of Middle East Respiratory Syndrome (MERS).
\n \n\n \n \n13 December 2023
\n \n \n \nAn international network of researchers, led by NDM\u2019s Professor Helen McShane and Professor Samantha Sampson from Stellenbosch University, has recently been awarded a new UK Medical Research Council (MRC) grant to continue the network activities until 2027.
\n \n\n \n \n11 December 2023
\n \n \n \nThe first patient in Oxfordshire has been treated in an mRNA cancer vaccine trial at Oxford University Hospitals NHS Foundation trust (OUH). The trial, led locally by Dr Ketan Shah, consultant clinical oncologist at OUH, marks a significant milestone in the national cancer vaccine advance.
\n \n\n \n \n16 November 2023
\n \n \n \nThe Pandemic Sciences Institute has joined forces with the Science for Africa Foundation and the Mastercard Foundation to launch a call for applications to establish innovative networks of research excellence in epidemic and pandemic sciences across Africa.
\n \n\n \n \n9 November 2023
\n \n \n \nThe AIDS Clinical Trials Group is starting a study to test a new HIV treatment. The study will enrol participants who initiated HIV treatment shortly after getting infected with HIV.
\n \n\n \n \n8 November 2023
\n \n \n \nThe University of Oxford has announced a partnership with Danaher Corporation to develop a new test to enable precision medicine care for sepsis, a pathological immune response to infection that accounts for one in five deaths globally each year.
\n \n\n \n \n7 November 2023
\n \n \n \nThe Global Health Network and the British Society for Antimicrobial Chemotherapy (BSAC) have signed a Memorandum of Understanding (MoU) establishing a framework for collaboration that can maximise the impact of shared antimicrobial resistance education, policy and advocacy efforts.
\n \n\n \n \n6 November 2023
\n \n \n \nScientific advisors to the International Pandemic Preparedness Secretariat (IPPS) visited the University of Oxford\u2019s vaccine laboratories as part of a two-day meeting of the global coalition.
\n \n\n \n \n3 November 2023
\n \n \n \nThe Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford announced the launch of a new project to initiate early development of prototype vaccines against the Jun\u00edn virus. This is the first project to be initiated under CEPI and the University of Oxford\u2019s strategic partnership to accelerate global pandemic preparedness efforts.
\n \n\n \n \n2 November 2023
\n \n \n \nThe AELIX-002 study group research was awarded the European Hector Research Award in HIV for research on the therapeutic vaccine against HIV. The researchers include Prof Tom\u00e1\u0161 Hanke, Professor of Vaccine Immunology at the Jenner Institute at NDM.
\n \n\n \n \n1 November 2023
\n \n \n \nNDM\u2019s Oxford University Clinical Research Unit in Viet Nam will be a part of a new initiative aimed at developing a strategic roadmap for Ho Chi Minh City to become a regional Health Innovation Hub. The project, supported by a \u00a375,000 grant from the UK Government, is a strategic move to transform Ho Chi Minh City into ASEAN's leading health innovation centre.
\n \n\n \n \n30 October 2023
\n \n \n \nThe Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial, which discovered four effective treatments for COVID-19, has now expanded to investigate treatments for influenza (flu). The RECOVERY trial is a collaboration between the Nuffield Department of Medicine and the Nuffield Department of Population Health.
\n \n\n \n \n26 October 2023
\n \n \n \nThe Broad One Health Endectocide-based Malaria Intervention in Africa project (BOHEMIA) begins its mass drug administration (MDA) activities in Kenya\u2019s Kwale County. BOHEMIA is a consortium of multiple international organisations including the Centre for Tropical Medicine and Global Health at NDM.
\n \n\n \n \n20 October 2023
\n \n \n \nIn collaboration with Ho Chi Minh City's healthcare sector, NDM's Oxford University Clinical Research Unit has successfully identified the primary agent causing the outbreak of pink eye disease. Testings revealed an unexpected finding: enterovirus was the primary agent, contrary to previous reports from Vietnam wherein adenovirus was the culprit.
\n \n\n \n \n10 October 2023
\n \n \n \nToday Oxford University has launched a new global collaboration backed by \u00a38 million funding from UK Research and Innovation (UKRI). The project will be spearheaded by Professor Teresa Lambe, Professor of Vaccinology and Immunology and Calleva Head of Vaccine Immunology in the Department of Paediatrics and Professor Paul Klenerman, Sidney Truelove Professor of Gastroenterology and Director of the Translational Gastroenterology Unit at NDM, both of whom are Principal Investigators at NDM\u2019s Pandemic Sciences Institute.
\n \n\n \n \n2 October 2023
\n \n \n \nThe World Health Organization\u2019s Strategic Advisory Group of Experts (SAGE) and Malaria Policy Advisory Group (MPAG) have recommended Oxford\u2019s R21/Matrix-M\u2122 malaria vaccine for use. The highly effective vaccine developed by the Jenner Institute and the Serum Institute of India has demonstrated high efficacy with a reassuring safety profile.
\n \n\n \n \n28 September 2023
\n \n \n \nA delegation from the Beijing Center for Disease Prevention and Control (Beijing CDC) visited the Chinese Academy of Medical Sciences Oxford Institute (COI) at NDM recently.
\n \n\n \n \n